MedTrace Logo

Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients

NCT02574091 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-07-13

No results posted yet for this study

Summary

This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of Icotinib Hydrochloride Cream in healthy adults and patients with mild to moderate psoriasis.

Conditions

Interventions

DRUG

1% icotinib hydrochloride cream

Topical administration for twice daily

DRUG

2% icotinib hydrochloride cream

Topical administration for twice daily.

DRUG

Placebo

Topical administration for twice daily.

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • Betta Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Christopher J Wynne · Christchurch Clinical Studies Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-26
Primary Completion
2017-02-19
Completion
2017-02-19

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02574091 on ClinicalTrials.gov